News
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...
Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...
The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...
Explore more
Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...
The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...
An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...
The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.
While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...
The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results